ORIC Pharmaceuticals, Inc. cash flow to debt ratio of -981.36% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

ORIC Pharmaceuticals, Inc.'s free cash flow has decreased 0.20% from $-113.85M last year to $-114.08M, signaling decreasing performance

ORIC Pharmaceuticals, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

ORIC Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 0.01 last year to 0.01 today, signaling strengthened financials

ORIC Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Interest expense is not separately reported in ORIC Pharmaceuticals, Inc.'s latest filing, so interest coverage cannot be calculated.

ORIC Pharmaceuticals, Inc. has insufficient data to evaluate this check.

ORIC Pharmaceuticals, Inc.'s short-term assets of $288.47M exceed its short-term liabilities of $20.42M

ORIC Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

ORIC Pharmaceuticals, Inc.'s return on equity of -35.35%, is lower than 15.00%, indicating bad performance

ORIC Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

ORIC Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

ORIC Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

ORIC Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

ORIC Pharmaceuticals, Inc.'s yearly earnings has decreased 1.27% since last year from $-127.85M to $-129.47M, signaling decreasing performance

ORIC Pharmaceuticals, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -40.32% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

ORIC Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

ORIC Pharmaceuticals, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

ORIC Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

ORIC Pharmaceuticals, Inc. has insufficient data to evaluate this check.

ORIC Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ORIC Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

ORIC Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

ORIC Pharmaceuticals, Inc. has insufficient data to evaluate this check.

ORIC Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

ORIC Pharmaceuticals, Inc. has a price-to-book ratio of 3.86x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

ORIC Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue